Claim · 2024-06-04 · publication · Stated in source · Supported

XtalPi's Hong Kong prospectus of 4 June 2024 states that in 2016 it took part in a crystal structure prediction blind test held by Pfizer, which it says led to a long-term strategic master partnership with Pfizer.

One recorded claim. The claim panel gives its qualification, the source passages with their place in each source, and how it was checked.

What it connects

QuantumPharm Inc. Global Offering prospectus → states provision → company account: 2016 Pfizer crystal structure prediction blind test led to a long-term strategic partnership with Pfizer

Where it appears

No collection page holds this claim. It is listed with its records in the explorer.

Claim and evidence

QuantumPharm Inc. Global Offering prospectusstates provision ↓company account: 2016 Pfizer crystal structure prediction blind test led to a long-term strategic partnership with Pfizer

Machine-checked, not reviewed by an editorStated in sourceSupported

Supporting evidence: primary · 1 source

Provision: Statement · provision ID co-xtalpi-pfizer-2024
Date: 2024-06-04 · publication Records dated 2024 →

Scope and limitsThe issuer's account; "achieved accurate prediction" is XtalPi's characterisation, not an independent result, and the record is not Pfizer's statement.

The evidence 01

primary sourceSupports the claim

QuantumPharm Inc. Global Offering (Hong Kong prospectus)

QuantumPharm Inc. (now XtalPi Holdings Limited), published on HKEXnews · 2024-06-04

Cite the original source

Cite the original document, not Selekoa. Check these details against it.

Source excerpt

“In 2016, we participated in a global crystal structure prediction (“CSP”) blind test held by Pfizer and achieved accurate prediction, which led to our long-term strategic master partnership in technological innovation and drug R&D with Pfizer.”

Location in source Summary, "Overview" (PDF p. 10)

How it was read Retrieved directly from the publisher

Machine-checked · 2026-10-30

Source details and check notes

Authors: QuantumPharm Inc. (now XtalPi Holdings Limited), published on HKEXnews
Version: Retrieved for the candidate pack on 2026-10-30 (SHA-256 fce5a6aee28817f6b479cf259cfe75d65f48b1519f6173f21cf183bb767a93df). HKEXnews PDF 2024060400065, English prospectus dated June 4, 2024, as served on 2026-10-30.
Canonical address: Open the canonical source ↗
Accessed: 2026-10-30
Language: English (en)
Attribution: QuantumPharm Inc. (now XtalPi Holdings Limited), published on HKEXnews, “QuantumPharm Inc. Global Offering (Hong Kong prospectus)”, 2024-06-04.
Reuse: No open redistribution licence asserted. Bibliographic metadata, editorial paraphrases and short attributed quotations (at most 50 words each). Recheck terms before wider redistribution.
Check notes: Candidate pack passage, AI in biology (research/ai-in-biology). The quotation (36 words) matched the text retrieved for the candidate pack on 2026-10-30. Matching ignored differences of whitespace, case, quotation marks, dashes and Unicode compatibility forms, so the source’s typography can differ. No human editorial review.

Status and meaning

Editorial status. Not reviewed by an editor. An exploratory record that no editor has accepted. This status does not say whether a person has read any linked passage. Each evidence record above shows how it was checked.

Relation. An exact framework edition, or another document with an exact expression, states one provision: a capability threshold or risk level and its trigger, a required safeguard or action, a decision authority (who decides, recommends, can overrule or is informed), a stated exception, or another statement of its content, such as a licence term or a prospectus statement. The passage records what the document says, not implementation, compliance or effectiveness. Provisions with the same key align across editions of one family.

Date. Dated by the prospectus; the 2016 test is the company's account of an earlier event, and no partnership date is given.

Record ID aib-co-xtalpi-pfizer-2024